INOVIQ

INOVIQ Net Margin

The Net Profit Margin of INOVIQ (IIQ.AX) as of Oct 20, 2026 is -1,737.11 %. In the previous year, Net Profit Margin was -381.88 % — a change of 354.89% (lower).

Net Margin

-1,737.11 %

YoY

354.89%

Last updated:

Net Profit Margin of INOVIQ is 2026 -1,737.11 % . Net Profit Margin of INOVIQ was 2025 -381.88 % . It decreases by 354.89% lower compared to the previous year.

INOVIQ's net margin stands at -1,737.1%, up from -6,575.0% several years earlier.

The INOVIQ Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2019
-19,670.94 AUD
Jan 1, 2020
-3,306.79 AUD
Jan 1, 2021
-877.34 AUD
Jan 1, 2022
-6,575.01 AUD
Jan 1, 2023
-2,252.43 AUD
Jan 1, 2024
-1,224.78 AUD
Jan 1, 2025
-381.88 AUD
Jan 1, 2026
-1,737.11 AUD
The INOVIQ Net Margin history
YEARNet MarginYoY
-1,737.11 %+354.89%
-381.88 %-68.82%
-1,224.78 %-45.62%
-2,252.43 %-65.74%
-6,575.01 %+649.42%
-877.34 %-73.47%
-3,306.79 %-83.19%
-19,670.94 %+575.74%
-2,911.02 %-50.78%
-5,914.81 %+15,506.64%
-37.90 %-87.46%
-302.19 %+3,341.32%
-8.78 %-102.75%
319.47 %+57,689.67%
0.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

INOVIQ Stock analysis

What does INOVIQ do? INOVIQ Ltd. provides medical services through its two market products, the hTERT ICC test and EXO-NET Pan-Exosome. The hTERT ICC test is an immunocytochemistry assay registered for detecting human telomerase reverse transcriptase in cytopathology samples, used as an adjunct to urine cytology to help resolve indeterminate results and identify patients at higher risk of bladder cancer. EXO-NET Pan-Exosome is a research use only tool for isolating exosomes from body fluids like plasma, urine, and saliva. The company's cancer diagnostic pipeline includes blood tests under development for early detection and monitoring of ovarian, breast, prostate, and other cancers. The hTERT ICC test is purchased by healthcare providers for diagnostic use in resolving ambiguous cytology results, particularly in bladder cancer risk assessment. EXO-NET Pan-Exosome is sold to research institutions and laboratories for exosome isolation in scientific studies. The blood tests in development target medical professionals involved in cancer diagnostics and monitoring, aiming to support earlier detection of multiple cancer types. INOVIQ Ltd. generates revenue primarily through the sale of its diagnostic products to medical facilities and research entities. The hTERT test serves clinical settings for bladder cancer risk identification, while EXO-NET supports research applications in exosome analysis. The company's pipeline products are positioned for future commercialization in the cancer diagnostics market. INOVIQ is one of the most popular companies on Eulerpool.

Frequently Asked Questions about INOVIQ stock

Net Profit Margin of INOVIQ is -1,737.11 % in 2026.

Net Profit Margin of INOVIQ changed from -381.88 % to -1,737.11 %, representing a 354.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin INOVIQ since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's INOVIQ with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — INOVIQ

All Key Metrics — INOVIQ